Current Alzheimer Research


Prof. Debomoy K. Lahiri
(16607 citations)
Neuroscience Research Center
Indianapolis, IN 46202

Nobel Laureates on Editorial Board

Prof. Jean-Marie Lehn

Prof. Ferid Murad

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 3 Issue: 3, July

Partnerships Between Philanthropy, Government and Investors are Needed to Advance Drug Discovery for Neurodegenerative Diseases

Volume:3   Issue: 3
Pp: 175-176
Lorenzo M Refolo and Howard M Fillit
DOI: 10.2174/156720506777632853
Published on: 01 March, 2012

Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation

Volume:3   Issue: 3
Pp: 179-183
Daniela Puzzo and Ottavio Arancio
DOI: 10.2174/156720506777632871
Published on: 01 March, 2012

TGF-β Pathway as a Potential Target in Neurodegeneration and Alzheimers

Volume:3   Issue: 3
Pp: 191-195
Tony Wyss-Coray
DOI: 10.2174/156720506777632916
Published on: 01 March, 2012

Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate

Volume:3   Issue: 3
Pp: 197-199
Illana Gozes and Irit Spivak-Pohis
DOI: 10.2174/156720506777632790
Published on: 01 March, 2012

The Pharmacology of Aminoadamantane Nitrates

Volume:3   Issue: 3
Pp: 201-204
Yuqiang Wang, Jerry Eu, Mark Washburn, Tong Gong, H.-S. Vincent Chen, W. Larrick James, Stuart A. Lipton, Jonathan S. Stamler, Gregory T. Went and Seth Porter
DOI: 10.2174/156720506777632808
Published on: 01 March, 2012

De Novo and Molecular Target-Independent Discovery of Orally Bioavailable Lead Compounds for Neurological Disorders open access plus

Volume:3   Issue: 3
Pp: 205-214
Laura K. Wing, Heather A. Behanna, Linda J. Van Eldik, D. Martin Watterson and Hantamalala Ralay Ranaivo
DOI: 10.2174/156720506777632844
Published on: 01 March, 2012

Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice

Volume:3   Issue: 3
Pp: 215-219
Mary L. Michaelis
DOI: 10.2174/156720506777632880
Published on: 01 March, 2012

RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine

Volume:3   Issue: 3
Pp: 221-227
Stephanie Tucker, Michelle Ahl, Hyun-Hee Cho, Sanghamitra Bandyopadhyay, Gregory D. Cuny, Ashley I. Bush, Lee E. Goldstein, David Westaway, Xudong Huang and Jack T. Rogers
DOI: 10.2174/156720506777632835
Published on: 01 March, 2012

Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes

Volume:3   Issue: 3
Pp: 229-235
Shyamala Mruthinti, Rosann F. Schade, Dean U. Harrell, Nidhi K. Gulati, S. Swamy-Mruthinti, Gregory P. Lee and Jerry J. Buccafusco
DOI: 10.2174/156720506777632899
Published on: 01 March, 2012

NO Chimeras as Therapeutic Agents in Alzheimers Disease

Volume:3   Issue: 3
Pp: 237-245
Gregory R.J. Thatcher, Brian M. Bennett and James N. Reynolds
DOI: 10.2174/156720506777632925
Published on: 01 March, 2012

Computational Models of the Hippocampal Region: Implications for Prediction of Risk for Alzheimers Disease in Non-demented Elderly

Volume:3   Issue: 3
Pp: 247-257
Mark A. Gluck, Catherine E. Myers, Michelle M. Nicolle and Sterling Johnson
DOI: 10.2174/156720506777632826
Published on: 01 March, 2012

Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents

Volume:3   Issue: 3
Pp: 259-266
Chunying Wu, Lisheng Cai, Jingjun Wei, Victor W. Pike and Yanming Wang
DOI: 10.2174/156720506777632862
Published on: 01 March, 2012